Zynerba cites 'tripledemic' for PhIII delay of a cannabinoid drug that's failed multiple times
Zynerba Pharmaceuticals’ cannabinoid drug has flamed out multiple times over the years, and the biotech’s latest attempt at proving the gel’s efficacy is being hampered by what’s been referred to as the “tripledemic.”
The Pennsylvania biotech cited the rise in RSV, influenza and Covid-19 cases as the reason for why its Phase III trial will no longer read out in the second half of 2023. The timeline has been pushed to the first half of 2024, Zynerba said Wednesday morning. That also means a second Phase III in another indication is being pushed back as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.